Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Anlotinib + nab-Paclitaxel in advanced mucosal melanoma
NCT04979585Phase 2Unknown
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in mucosal melanoma (MM). Status: unknown.
02
Drugs
camrelizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04979585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979585.